Literature DB >> 32016067

Role of immunotherapy in metastatic renal cell cancer: past, present and future.

Amos Lal1, Kamal Kant Sahu2, Vishal Jindal2, Ajay Kumar Mishra2, Ahmad Daniyal Siddiqui2.   

Abstract

Entities:  

Year:  2019        PMID： 32016067      PMCID： PMC6976479          DOI： 10.21037/atm.2019.09.95

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  33 in total

1.  CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.

Authors:  Bernard Escudier; Padmanee Sharma; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Howard Gurney; Frede Donskov; Katriina Peltola; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Huanyu Zhao; Ian M Waxman; Robert J Motzer
Journal:  Eur Urol       Date:  2017-03-03       Impact factor: 20.096

2.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Brian I Rini; Elizabeth R Plimack; Viktor Stus; Rustem Gafanov; Robert Hawkins; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Anna Kryzhanivska; Igor Bondarenko; Sergio J Azevedo; Delphine Borchiellini; Cezary Szczylik; Maurice Markus; Raymond S McDermott; Jens Bedke; Sophie Tartas; Yen-Hwa Chang; Satoshi Tamada; Qiong Shou; Rodolfo F Perini; Mei Chen; Michael B Atkins; Thomas Powles
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

3.  Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma.

Authors:  Tarek M Mekhail; Rony M Abou-Jawde; Gabriel Boumerhi; Sareena Malhi; Laura Wood; Paul Elson; Ronald Bukowski
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

4.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

5.  A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects.

Authors:  Wolfram E Samlowski; Ryan Petersen; Salvatore Cuzzocrea; Heather Macarthur; Damali Burton; John R McGregor; Daniela Salvemini
Journal:  Nat Med       Date:  2003-05-05       Impact factor: 53.440

6.  Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup.

Authors:  N J Vogelzang; E R Priest; L Borden
Journal:  J Urol       Date:  1992-10       Impact factor: 7.450

7.  Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Authors:  J Connor Wells; Igor Stukalin; Craig Norton; Sandy Srinivas; Jae Lyun Lee; Frede Donskov; Georg A Bjarnason; Haru Yamamoto; Benoit Beuselinck; Brian I Rini; Jennifer J Knox; Neeraj Agarwal; D Scott Ernst; Sumanta K Pal; Lori A Wood; Aristotelis Bamias; Ajjai S Alva; Ravindran Kanesvaran; Toni K Choueiri; Daniel Y C Heng
Journal:  Eur Urol       Date:  2016-06-16       Impact factor: 20.096

8.  Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.

Authors:  Asim Amin; Arkadiusz Z Dudek; Theodore F Logan; Raymond S Lance; Jeffrey M Holzbeierlein; Jennifer J Knox; Viraj A Master; Sumanta K Pal; Wilson H Miller; Lawrence I Karsh; Irina Y Tcherepanova; Mark A DeBenedette; W Lee Williams; Douglas C Plessinger; Charles A Nicolette; Robert A Figlin
Journal:  J Immunother Cancer       Date:  2015-04-21       Impact factor: 13.751

9.  Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series.

Authors:  Padmastuti Akella; Sundaravadivel Loganathan; Vishal Jindal; Jamal Akhtar; Amos Lal
Journal:  Respir Med Case Rep       Date:  2018-11-12

10.  Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Authors:  Asim Amin; Elizabeth R Plimack; Marc S Ernstoff; Lionel D Lewis; Todd M Bauer; David F McDermott; Michael Carducci; Christian Kollmannsberger; Brian I Rini; Daniel Y C Heng; Jennifer Knox; Martin H Voss; Jennifer Spratlin; Elmer Berghorn; Lingfeng Yang; Hans J Hammers
Journal:  J Immunother Cancer       Date:  2018-10-22       Impact factor: 13.751
View more
  1 in total

1.  Enhanced Recovery After Surgery Protocol Optimizes Results and Cost of Laparoscopic Radical Nephrectomy.

Authors:  Siming Chen; Zhiwen He; Shijie Yao; Kangping Xiong; Jiageng Shi; Gang Wang; Kaiyu Qian; Xinghuan Wang
Journal:  Front Oncol       Date:  2022-04-04       Impact factor: 5.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.